Antibodies and their derivatives can protect plants and animals--including humans--against viruses. Members of this class of drugs are usually highly specific against components of a particular virus, and mutations in the virus that change these components can make them ineffective. An article published on June 26th in PLOS Pathogens now reports that a mini antibody called 3D8 scFv can degrade (or chew up) viral DNA and RNA regardless of specific sequences and protect mammalian cells and genetically manipulated mice against different viruses.
Sukchan Lee, from Sungkyunkwan University, Suwon, Korea, and colleagues had previously discovered that 3D8 has both DNase and RNase activity (that is, it can degrade both), and that it can inhibit viruses under certain circumstances. In this study, they genetically manipulated cells and mice to produce 3D8.
They show that when the right amount of 3D8 is produced, the cells and the animals become resistant to two different and normally deadly viruses, namely herpes simplex virus and pseudorabies virus. To protect the animals, it appears critical that the right dose of 3D8 is present in the tissues initially infected by the viruses; once the virus has started to multiply and spread, it seems that 3D8 can no longer contain it efficiently.
When the researchers examined the mechanisms underlying the protective activity, they found that 3D8 fights viruses at two different places and stages of the viral life cycle. In the cell nucleus, it degrades viral DNA to prevent it from getting copied. In the cytoplasm (the area outside of the nucleus), it destroys RNA destined to be used for the production of virus components.
As the researchers discuss, the correct 3D8 dose is critical to destroy only viral DNA and RNA (but not their host genetic material), and additional research is needed to understand the basis for this selective activity. Moreover, to protect the host, 3D8 needs to be present at the time of viral infection and in the right tissues. That said, they conclude that "3D8 scFv is a candidate antiviral protein that can potentially confer resistance to a broad spectrum of animal and plant viruses". They also suggest that "this strategy may facilitate control of...viruses uncharacterized at the molecular level, regardless of their genome type or variations in gene products".
Please contact firstname.lastname@example.org if you would like more information about our content and specific topics of interest.
All works published in PLOS Pathogens are open access, which means that everything is immediately and freely available. Use this URL in your coverage to provide readers access to the paper upon publication:
Related Image for Press Use:
Caption: New antiviral drug against broad viruses.
Image Credit: Sukchan Lee and colleagues
Authors and Affiliations:
Gunsup Lee, Sungkyunkwan University, Suwon, Korea; National Institute of Horticultural and Herbal Science, Korea
Jaelim Yu, Sungkyunkwan University, Suwon, Korea
Seungchan Cho, Sungkyunkwan University, Suwon, Korea
Sung-June Byun, National Institute of Animal Science, Korea
Dae Hyun Kim, National Institute of Horticultural and Herbal Science, Korea
Taek-Kyun Lee, Korea Institute of Ocean Science and Technology, Korea
Myung-Hee Kwon, Ajou University School of Medicine, Korea
Sukchan Lee, Sungkyunkwan University, Suwon, Korea
Funding: This study was supported, in part, by the Next Generation BioGreen21 program (PJ008146) from the Rural Development Administration in Korea and the Korea Institute of Ocean Science and Technology project (No. PE99154) of Korea. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
Citation: Lee G, Yu J, Cho S, Byun S-J, Kim DH, et al. (2014) A Nucleic-Acid Hydrolyzing Single Chain Antibody Confers Resistance to DNA Virus Infection in HeLa Cells and C57BL/6 Mice. PLOS Pathog 10(6): e1004208. doi:10.1371/journal.ppat.1004208